Quark Pharmaceuticals Is A Pharmaceutical Company Focused On Developing Rna Interferencernaibased Treatments For Various Chronic And Acute Diseasesfounded In 1993The Company Is Currently Based In Ness Zionaisraelquark Specializes In Using Small Interfering Rnasirnato Silence Specific Geneswhich Is Central To Its Therapeutic Development Efforts The Company Has Engaged In Significant Collaborationsincluding A Partnership With Pfizer To Develop Drugs Targeting The Rtp801 Genequark Also Works With The Center For Hearing & Deafness At The University Of New York At Buffalo To Explore The Prevention Of Chemotherapy Induced Hearing Loss Using Sirnaadditionallyquark Has Licensed Its Compound Bt16 To Sanwa For Treating Dyslipidemia And Has Made Discoveries Related To The Ero 1L Alpha Genewhich May Have Implications For Cancer And Other Conditions Related To Hypoxiaquark Pharmaceuticals Has Raised $37 Million In Fundingwith Notable Investors Including Sbi Investment And Mitsubishi Ufj Capitalthe Company Has Filed Numerous Patents Related To Rnai Technologyunderscoring Its Commitment To Innovative Research In Molecular Biology
